368
Participants
Start Date
June 30, 2021
Primary Completion Date
December 12, 2024
Study Completion Date
December 12, 2024
Kesimpta
Prospective observational cohort study. There is no treatment allocation.
Novartis Investigative Site, Chiba
Novartis Investigative Site, Sakai
Novartis Investigative Site, Ichinomiya
Novartis Investigative Site, Nagakute
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Tokoname
Novartis Investigative Site, Toyohashi
Novartis Investigative Site, Hachinohe
Novartis Investigative Site, Hachinohe
Novartis Investigative Site, Hirosaki
Novartis Investigative Site, Ichikawa
Novartis Investigative Site, Narita
Novartis Investigative Site, Yachiyo
Novartis Investigative Site, Tōon
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kurume
Novartis Investigative Site, Omuta
Novartis Investigative Site, Gifu
Novartis Investigative Site, Maebashi
Novartis Investigative Site, Maebashi
Novartis Investigative Site, Fukuyama
Novartis Investigative Site, Asahikawa
Novartis Investigative Site, Hakodate
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sunagawa
Novartis Investigative Site, Kobe
Novartis Investigative Site, Mito
Novartis Investigative Site, Tsuchiura
Novartis Investigative Site, Ichinoseki
Novartis Investigative Site, Ichinoseki
Novartis Investigative Site, Morioka
Novartis Investigative Site, Kagoshima
Novartis Investigative Site, Kagoshima
Novartis Investigative Site, Kanoya
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Nankoku
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Kesennuma
Novartis Investigative Site, Sendai
Novartis Investigative Site, Sendai
Novartis Investigative Site, Nagano
Novartis Investigative Site, Nagano
Novartis Investigative Site, Sasebo
Novartis Investigative Site, Kashihara
Novartis Investigative Site, Tenri
Novartis Investigative Site, Niigata
Novartis Investigative Site, Ōita
Novartis Investigative Site, Kurashiki
Novartis Investigative Site, Okayama
Novartis Investigative Site, Fujiidera
Novartis Investigative Site, Moriguchi
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Ōsaka-sayama
Novartis Investigative Site, Suita
Novartis Investigative Site, Kawagoe
Novartis Investigative Site, Koshigaya
Novartis Investigative Site, Saitama
Novartis Investigative Site, Wako
Novartis Investigative Site, Ohtsu
Novartis Investigative Site, Ōmihachiman
Novartis Investigative Site, Izumo
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Oyama
Novartis Investigative Site, Shimotsuga Gun
Novartis Investigative Site, Shimotsuke
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Edogawa City
Novartis Investigative Site, Fuchū
Novartis Investigative Site, Kiyose
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Nakano City
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Toyama
Novartis Investigative Site, Wakayama
Novartis Investigative Site, Kudamatsu
Novartis Investigative Site, Shūnan
Novartis Investigative Site, Ube
Novartis Investigative Site, Aomori
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Kobe
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Niigata
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY